<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04506008</url>
  </required_header>
  <id_info>
    <org_study_id>VICC SAR 2062</org_study_id>
    <nct_id>NCT04506008</nct_id>
  </id_info>
  <brief_title>Hypofractionated Radiotherapy Followed by Immediate Surgical Resection in the Treatment of Soft Tissue Sarcomas</brief_title>
  <official_title>Prospective Observational Trial of Neoadjuvant Hypofractionated Radiotherapy Followed by Immediate Surgical Resection in the Treatment of Soft Tissue Sarcomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt-Ingram Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vanderbilt-Ingram Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The trial will use neoadjuvant hypofractionated radiotherapy followed by immediate surgical&#xD;
      resection in the treatment for soft tissue sarcoma. It will allow patients to be treated over&#xD;
      the course of 1-2 weeks with similar local control rates compared to the traditional 2-3&#xD;
      month timeline. Additionally, it is proposed that this will be possible without increasing&#xD;
      the risk of wound complications compared with a traditional 5-6 week course of pre-operative&#xD;
      radiation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Objectives:&#xD;
&#xD;
      Primary:&#xD;
&#xD;
      -To assess the efficacy of hypofractionated radiotherapy followed by immediate surgical&#xD;
      resection in the treatment of soft tissue sarcoma&#xD;
&#xD;
      Secondary:&#xD;
&#xD;
      - To assess the side effect profile, late side effects criteria, and major and minor&#xD;
      post-operative complication rates.&#xD;
&#xD;
      Exploratory:&#xD;
&#xD;
        -  To assess patient related factors which may influence wound complication rates.&#xD;
&#xD;
        -  To assess patient-reported functional and satisfaction outcomes.&#xD;
&#xD;
        -  To assess margin status and percent necrosis at time of surgery.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 11, 2021</start_date>
  <completion_date type="Anticipated">December 2025</completion_date>
  <primary_completion_date type="Anticipated">December 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Local control rate</measure>
    <time_frame>Approximately 2 years</time_frame>
    <description>Incidence of recurrence compared to historical controls</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Post- Operative Complication rate</measure>
    <time_frame>Approximately 2 years</time_frame>
    <description>Measured by incidence of would complications compared to historical controls</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of acute dermatitis</measure>
    <time_frame>Approximately 90 days</time_frame>
    <description>RTOG Score (0-4 (0=best 4=worst)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure of late functional side effects</measure>
    <time_frame>Approximately 2 years</time_frame>
    <description>Musculoskeletal Tumour Society Rating Scale (0-5 (5=best 0=worst)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure of late skin side effects</measure>
    <time_frame>Approximately 2 years</time_frame>
    <description>RTOG Late Radiation Skin Toxicity Score (0-4 (0=best 4=worst)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure of late subcutaneous side effects</measure>
    <time_frame>Approximately 2 years</time_frame>
    <description>RTOG Late Radiation Subcutaneous Tissue Toxicity Score (0-4 (0=best 4=worst)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Soft Tissue Sarcomas</condition>
  <arm_group>
    <arm_group_label>Hypofractionated Radiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hypofractionated Radiotherapy followed by immediate surgical resection</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Hypofractionated Radiotherapy</intervention_name>
    <description>Treated over the course of 1-2 weeks</description>
    <arm_group_label>Hypofractionated Radiotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologic diagnosis of a soft tissue sarcoma of extremity, pelvis, chest wall or&#xD;
             trunk/abdominal wall (non-retroperitoneal location)&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  Patient must be deemed able to comply with radiation treatment and surgery&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with planned neoadjuvant chemotherapy&#xD;
&#xD;
          -  History of prior radiation to the same area to be irradiated&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Active collagen vascular disease or patients genetically predisposed to increased&#xD;
             radiation related side effects&#xD;
&#xD;
          -  Patients with metastatic disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric Shinohara, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Vanderbilt-Ingram Service for Timely Access</last_name>
    <phone>800-811-8480</phone>
    <email>cip@vumc.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Vanderbilt-Ingram Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vanderbilt-Ingram Service for Timely Access</last_name>
      <phone>800-811-8480</phone>
      <email>cip@vumc.org</email>
    </contact>
    <investigator>
      <last_name>Eric Shinohara, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>August 5, 2020</study_first_submitted>
  <study_first_submitted_qc>August 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 10, 2020</study_first_posted>
  <last_update_submitted>February 4, 2021</last_update_submitted>
  <last_update_submitted_qc>February 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt-Ingram Cancer Center</investigator_affiliation>
    <investigator_full_name>Eric Shinohara</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Hypofractionated Radiotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

